If Wegovy is denied, Zepbound may still be covered under a different formulary tier or vice versa
En resumen, cuidar de nuestra salud digestiva no solo implica prestar atencin a nuestra dieta, sino tambin asegurarnos de que nuestro cuerpo reciba los nutrientes adecuados para apoyar la funcin intestinal
Key TakeawaysThe number of people taking GLP-1 drugs to lose weight more than tripled in recent yearsThe percentage of non-diabetics taking GLP-1 drugs rose from 0.1% to 0.4% between 2018 and 2022That led to $5.8 billion in spending on the drugs in 2022.TUESDAY, April 1, 2025 (HealthDay News) -- The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent years, a new study says.The number of people without diabetes taking a GLP-1 drug more than tripled between 2018 and 2022 in the U.S., researchers reported March 31 in the Annals of Internal Medicine.Spending on these drugs reached $5.8 billion in 2022, with average prices consistently exceeding $1,500 per prescription, results show.Despite this, adoption remained limited, as only 1 in 250 U.S
Hence, early detection and consistent treatment can be a game-changer
